Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis.
Marc KrauseYikang ZhuMaximilian HuhnJohannes Schneider-ThomaIrene BighelliAdriani NikolakopoulouStefan LeuchtPublished in: European archives of psychiatry and clinical neuroscience (2018)
Amisulpride is the only antipsychotic that outperformed placebo in the treatment of predominant negative symptoms, but there was a parallel reduction of depression. Cariprazine was better than risperidone in a large trial that was well-controlled for secondary negative symptoms, but the trial was sponsored by its manufacturer. Future trials should apply scientifically developed definitions such as the deficit syndrome and the persistent negative symptoms concept.